Abstract:Background: Stroke is a common neurological disorder that disproportionately affects middle-aged and elderly individuals, leading to significant disability and mortality. Recently, human blood metabolites have been discovered to be useful in unraveling the underlying biological mechanisms of neurological disorders. Therefore, we aimed to evaluate the causal relationship between human blood metabolites and susceptibility to stroke. Methods: Summary data from genome-wide association studies (GWASs) of serum metabolites and stroke and its subtypes were obtained separately. A total of 486 serum metabolites were used as the exposure. Simultaneously, 11 different stroke phenotypes were set as the outcomes, including any stroke (AS), any ischemic stroke (AIS), large artery stroke (LAS), cardioembolic stroke (CES), small vessel stroke (SVS), lacunar stroke (LS), white matter hyperintensities (WMH), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), transient ischemic attack (TIA), and brain microbleeds (BMB). A two-sample Mendelian randomization (MR) study was conducted to investigate the causal effects of serum metabolites on stroke and its subtypes. The inverse variance-weighted MR analyses were conducted as causal estimates, accompanied by a series of sensitivity analyses to evaluate the robustness of the results. Furthermore, a reverse MR analysis was conducted to assess the potential for reverse causation. Additionally, metabolic pathway analysis was performed using the web-based MetOrigin. Results: After correcting for the false discovery rate (FDR), MR analysis results revealed remarkable causative associations with 25 metabolites. Further sensitivity analyses confirmed that only four causative associations involving three specific metabolites passed all sensitivity tests, namely ADpSGEGDFXAEGGGVR* for AS (OR: 1.599, 95% CI 1.283-1.993, p = 2.92 × 10-5) and AIS (OR: 1.776, 95% CI 1.380-2.285, p = 8.05 × 10-6), 1-linoleoylglycerophosph-oethanolamine* for LAS (OR: 0.198, 95% CI 0.091-0.428, p = 3.92 × 10-5), and gamma-glutamylmethionine* for SAH (OR: 3.251, 95% CI 1.876-5.635, p = 2.66 × 10-5), thereby demonstrating a high degree of stability. Moreover, eight causative associations involving seven other metabolites passed both sensitivity tests and were considered robust. The association result of one metabolite (glutamate for LAS) was considered non-robust. As for the remaining metabolites, we speculate that they may potentially possess underlying causal relationships. Notably, no common metabolites emerged from the reverse MR analysis. Moreover, after FDR correction, metabolic pathway analysis identified 40 significant pathways across 11 stroke phenotypes. Conclusions: The identified metabolites and their associated metabolic pathways are promising circulating metabolic biomarkers, holding potential for their application in stroke screening and preventive strategies within clinical settings.

Twenty-three medication-taking traits and stroke: A comprehensive Mendelian randomization study

Cardiac Troponin I and Risk of Stroke A Mendelian Randomization Study

Genetic Insights into the Risk of Metabolic Syndrome and Its Components on Stroke and Its Subtypes: Bidirectional Mendelian Randomization.

Genetic determinants of circulating metabolites and the risk of stroke and its subtypes

Dissecting Causal Relationships Between Dietary Habits and Diverse Subtypes of Stroke: Mendelian Randomization Study

Causal Relations Between Exposome and Stroke: A Mendelian Randomization Study.

Attention-deficit/hyperactivity Disorder and Ischemic Stroke: A Mendelian Randomization Study.

Association of metabolites on ischemic stroke subtypes: a 2-sample Mendelian randomization study

Mendelian Randomization Study of Heart Failure and Stroke Subtypes

Assessing the causal effect of genetically predicted metabolites and metabolic pathways on stroke

Associations of lipids and lipid-lowering drugs with risk of stroke: a Mendelian randomization study

Association Between Blood Pressure and Different Antihypertensive Drugs with Outcome after Ischemic Stroke: A Mendelian Randomization Study.

Dissecting Causal Relationships Between Gut Microbiota, Blood Metabolites, and Stroke: A Mendelian Randomization Study

Causal relationship between novel antidiabetic drugs and ischemic stroke: a drug-targeted Mendelian randomization study

Modifiable risk factors mediate the effect of gastroesophageal reflux disease on stroke and subtypes: A Mendelian randomization study

Abstract P656: Cardioembolic Risk Factors and Ischemic Stroke a Mendelian Randomization Analysis

A Mendelian randomization analysis of the relationship between cardioembolic risk factors and ischemic stroke

Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes

Exploring the Causality of Type 1 Diabetes and Stroke Risk: A Mendelian Randomization Study and Meta-analysis

Multi-omics combined to investigate potential druggable therapeutic targets for stroke: A systematic Mendelian randomization study and transcriptome verification

The Mediating Role of Atrial Fibrillation in Causal Associations Between Risk Factors and Stroke: a Mendelian Randomization Study.